The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results